Orthopediatrics Corp (KIDS) · Oct 27, 2026 · Earnings

OrthoPediatrics earnings beat on revenue as margins hold and losses narrow

Beat — Revenue $72.7M vs ~$68.5M consensus; adjusted EPS -$0.23 in line

OrthoPediatrics earnings show a revenue beat and narrower losses, while 2026 guidance remains unchanged and the product launch cycle advances.

OrthoPediatrics is scaling a specialized pediatric-orthopedic implant and bracing platform, with a broad product portfolio and a multi-year launch cycle intended to improve growth and operating leverage. The filing’s real update is that the commercial engine is accelerating while profitability is beginning to improve, though the company is not yet consistently cash-generative.

MetricQ3 2025Q3 2026Change / comparison
Revenue$61.2M$72.7M+19%; above published consensus of ~$68.5M
Gross profit$45.3M$54.0MGross margin held at 74%
Operating loss$(9.4)M$(4.2)MLoss narrowed
Net loss$(11.8)M$(5.9)MLoss narrowed
GAAP diluted EPS$(0.50)$(0.25)Better year over year
Adjusted diluted EPS$(0.24)$(0.23)In line with published consensus of ~$0.23 loss
Adjusted EBITDA$6.2M$6.9MImproved
FY2026 revenue guidance—$270M–$273MReaffirmed
FY2026 adjusted EBITDA—~$25MReaffirmed
FY2026 free cash flow—Breakeven targetReaffirmed

Revenue is the clear upside surprise. Third-quarter revenue rose 19% to $72.7 million, ahead of the roughly $68.5 million published consensus, while gross margin stayed at 74%. The result supports the company’s thesis that new products, broader hospital penetration, and higher utilization of deployed instrument sets can drive growth without immediate gross-margin dilution.

The earnings quality improved, but this was not an across-the-board beat. Adjusted EPS was a $0.23 loss, essentially matching the published expectation, while adjusted EBITDA increased to $6.9 million from $6.2 million. GAAP net loss also narrowed to $5.9 million from $11.8 million, helped by lower restructuring and impairment charges. 〔0〕 That makes the quarter modestly better than expected overall, but the positive read is driven mainly by revenue and operating improvement rather than an earnings surprise.

The strategic story is advancing, not changing. Management describes a “multi-year product super cycle” with additional launches planned across trauma, scoliosis, bracing, and enabling technology. 〔1〕 The presentation also points to upcoming launches extending into the first and second halves of 2027, so the business remains in an investment-and-expansion phase rather than a mature profit-maximization phase.

Cash conversion is still the main unfinished piece. The company continues to target free-cash-flow breakeven for full-year 2026, but it held $44.9 million of cash and short-term investments against $98.4 million of debt at September 30, 2026. 〔2〕 Reaffirming breakeven matters because it preserves the existing growth plan, but it does not yet prove that the model can fund its product launches and instrument-set deployments internally.

Bottom line: This is a modestly positive earnings update: revenue beat expectations, margins held, and operating losses narrowed, while adjusted EPS merely met the bar. The broader product-cycle thesis remains intact, but cash breakeven is still a target rather than a completed milestone.

What to watch next

Q4/FY2026 results, early 2027

Original filing on SEC EDGAR

More Orthopediatrics Corp news

OrthoPediatrics earnings beat on revenue as margins hold and losses narrow | KIDS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.